M&A Deal Summary

Genmab Acquires ProfoundBio

On April 3, 2024, Genmab acquired life science company ProfoundBio for 1.8B USD

Acquisition Highlights
  • This is Genmab’s 1st transaction in the Life Science sector.
  • This is Genmab’s largest (disclosed) transaction.
  • This is Genmab’s 1st transaction in the United States.
  • This is Genmab’s 1st transaction in Washington.

M&A Deal Summary
Date 2024-04-03
Target ProfoundBio
Sector Life Science
Buyer(s) Genmab
Deal Type Add-on Acquisition
Deal Value 1.8B USD
Advisor(s) BofA Securities
Morgan Stanley (Financial)
Cooley
Jun He Law (Legal)

Target

ProfoundBio

Seattle, Washington, United States
ProfoundBio is a clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors. ProfoundBio is based in Seattle, Washington.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genmab

Valby, Denmark
Category Company
Founded 1999
Sector Life Science
Revenue 16.5B DKK (2023)
DESCRIPTION

Genmab is an international biotechnology company using its antibody technology platform to offer bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function-enhanced antibodies, and antibody-drug conjugates. Genmab was formed in 1999 and is headquartered in Copenhagen, Denmark.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Washington) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal